Medytox's fat reduction injection, NUVIJU, has surpassed 10,000 vials sold, quickly establishing its presence in the market with its differentiated safety and ease of use based on a domestic new drug. Medytox announced on June 17 that NUVIJU exceeded 10,000 vials in cumulative sales just two months after its launch.
NUVIJU is the first new drug in the domestic medical aesthetic market approved for the treatment of moderate to severe submental fat. It has been authorized as the 40th domestic new drug by the Ministry of Food and Drug Safety.
The product uses colic acid as its main ingredient, focusing on reducing side effects such as swelling and bruising. It also minimizes pain by maintaining a pH level similar to that of the human body (7.4) and excludes certain chemical excipients to reduce skin irritation.
NUVIJU has demonstrated its efficacy and safety through a large-scale Phase 3 clinical trial. In the trial involving 240 patients with moderate to severe submental fat, those receiving the treatment showed an improvement rate of 88.57% for at least one grade of fat reduction, compared to 32.43% in the placebo group. The rate of improvement of two grades or more was 46.67% in the treatment group versus 5.41% in the placebo group.
Medytox confirmed through additional non-clinical tests that the levels of stress hormones such as corticosteroids and catecholamines in the blood, as well as the expression of pain-related receptors in skin tissue, were significantly lower in the treatment group compared to the control group. The company plans to strengthen its aesthetic portfolio and expand its market competitiveness through NUVIJU.
A Medytox official stated, "We will actively respond to market demand and enhance our differentiated brand competitiveness through various marketing activities."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.